In Vitro Human Tissue-Engineered Blood Vessel Disease Model of Progeria
早衰症体外人体组织工程血管疾病模型
基本信息
- 批准号:9759965
- 负责人:
- 金额:$ 46.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2021-07-31
- 项目状态:已结题
- 来源:
- 关键词:20 year oldAddressAgingAlternative SplicingAnimal ModelAnimalsAntisense OligonucleotidesApoptosisArterial Fatty StreakArteriesAtherosclerosisAutophagocytosisBacterial Artificial ChromosomesBiological MarkersBlood VesselsCCI-779Cardiovascular DiseasesCardiovascular systemCause of DeathCell AgingCell CountCell Differentiation processCell NucleusCellsCellularityCessation of lifeClinical ResearchCombined Modality TherapyCoronary arteryCultured CellsDevelopmentDiseaseDisease ProgressionDisease modelDrug CombinationsDrug effect disorderEffectivenessEndotheliumEnsureEnvironmentEpigenetic ProcessExhibitsFarnesyl Transferase InhibitorFibroblastsFibrosisGene ExpressionGene MutationGenesHourHumanHuman EngineeringImpairmentIn VitroIndividualInflammationInflammation MediatorsInflammatoryKnock-inLamin Type ALaminsLesionLipidsLonafarnibMeasurementMedialMediatingMethylene blueMitochondriaMitosisModelingMusMyocardial InfarctionNuclearNuclear ProteinOxidative StressParentsPatientsPerfusionPharmaceutical PreparationsPharmacotherapyPhenotypePhysiologicalPoint MutationPravastatinPreparationProcessProductionProgeriaProteinsRNA SplicingRare DiseasesRunningRuptureShapesSignal PathwaySignal TransductionSiteSmooth Muscle MyocytesStrokeStructureSyndromeSystemTestingTherapeuticThickTissue EngineeringTreatment EffectivenessVascular DiseasesZoledronic Acidagedbiomarker identificationcalcificationcarbeneclinical candidatedrug candidatehistone methylationhuman tissueimprovedin vivoin vivo Modelinduced pluripotent stem cellmicrophysiology systemmouse modelnormal agingnovelnovel therapeuticsosteogenicprotein degradationresponse
项目摘要
Abstract
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare autosomal dominant disease of accelerated aging
which leads to death between 7 and 20 years of age. The disease arises from point mutations that produce an
alternately spliced form of the nuclear protein lamin A, known as progerin, that accumulates in the cell nucleus.
Mouse models of HGPS exhibit many phenotypical similarities with the HGPS lamin gene mutation, but
atherosclerosis does not develop, suggesting a limit to the suitability of animal models. Since cardiovascular
disease represents the primary cause of death among those with HGPS, we propose to use a novel tissue
engineered blood vessel microphysiological system to develop biomarkers for the disease and assess the
effectiveness of treatment against relevant physiological measurements. We have developed arteriolar-scale
endothelialized tissue-engineered blood vessels (TEBVs) using smooth muscle cells (SMCs) derived from
induced pluripotent stem cells (iPSCs) using healthy and HGPS cells. The TEBVs can be produced and
perfused at physiological flow conditions within a few hours of preparation and exhibit endothelial-mediated
vasoactivity and respond to inflammatory mediators. We can perform standard functional tests and examine
the effects of inflammatory signals, thus tracking the progression of the disease in the same vessel. The
HGPS-TEBVs provide a more realistic in vitro environment than cells cultured on plastic and can help advance
the process of discovering novel therapeutics and identification of biomarkers. In this project, we will test the
hypotheses that tissue-engineered blood vessels made with cells derived from individuals with HGPS
recapitulate in vitro the structure and activity found in vivo and can aid in assessing the effectiveness and
mode of action suitable drug candidates for clinical studies. In Aim 1, we will test the hypothesis that TEBVs
with cells derived from HGPS patients have the same phenotype as a mouse model of HGPS. We will assess
(1) the relative contribution of reduced cell number and oxidative stress on the altered function of HGPS-
TEBVs, (2) the effect of flow on EC NRF2 activity and oxidative genes it regulates, and (3) compare TEBV
structure and function with the mouse model for HGPS. Control conditions will consist of TEBVs prepared with
cells derived from a parent of one of the HGPS patients. In Aim 2, we will modify our system to run multiple
TEBVs simultaneously and test the hypothesis that combination therapies have been ineffective because they
have not restored SMC number, differentiation, and vasoactivity. In Aim 3, we will assess the suitability of
novel treatments for progeria to alter the HGPS phenotype in the TEBVs. We will examine the effect of agents
which improve mitochondrial function and or protein degradation, alone or in combination with lonafarnib and
anti-sense oligonucleotides that inhibit progerin production. Corresponding studies in mice will be performed to
assess whether the HGPS-TEBV model reproduces changes to vessels found in mouse model of HGPS.
摘要
Hutchinson-Gilford Progeria综合征(HGPS)是一种罕见的加速衰老的常染色体显性遗传病
这会导致7到20岁的儿童死亡。这种疾病是由点突变引起的
另一种剪接形式的核蛋白层蛋白A,称为孕激素,在细胞核中积累。
HGPS小鼠模型显示出许多与HGPS lamin基因突变的表型相似之处,但
动脉粥样硬化不会发展,这表明动物模型的适用性受到限制。自心血管疾病以来
疾病是HGPS患者的主要死亡原因,我们建议使用一种新的组织
工程血管微生理系统,为疾病开发生物标记物并评估
对照相关生理指标的治疗效果。我们已经开发出微动脉刻度
血管内皮化组织工程血管(TEBV)的构建
使用健康和HGPS细胞诱导多能干细胞(IPSCs)。TEBV可以生产和
在生理流动条件下准备几小时内灌流,并显示内皮细胞介导的
血管活性和对炎症介质的反应。我们可以执行标准的功能测试并检查
炎症信号的影响,从而在同一血管中跟踪疾病的进展。这个
HGPS-TEBV提供了比塑料上培养的细胞更逼真的体外环境,并有助于
发现新疗法和鉴定生物标记物的过程。在这个项目中,我们将测试
假设组织工程血管是由来自HGPS患者的细胞制成的
在体外概括在体内发现的结构和活性,有助于评估有效性和
作用方式适合临床研究的候选药物。在目标1中,我们将检验TEBV的假设
对于来自HGPS的细胞,患者具有与HGPS小鼠模型相同的表型。我们将评估
(1)细胞数量减少和氧化应激对HGPS功能改变的相对贡献
TEBV;(2)流动对EC NRF2活性及其调控基因的影响;(3)TEBV的比较
用于HGPS的鼠标模型的结构和功能。控制条件将由准备的TEBV组成
来自其中一名HGPS患者父母的细胞。在目标2中,我们将修改我们的系统以运行多个
TEBV同时测试联合疗法无效的假设,因为它们
尚未恢复SMC数量、分化和血管活性。在目标3中,我们将评估
早衰症的新治疗方法改变TEBV中的HGPS表型。我们将检查代理人的效果
可改善线粒体功能和/或蛋白质降解,单独或与氯那法尼和
抑制孕激素产生的反义寡核苷酸。将在老鼠身上进行相应的研究,以
评估HGPS-TEBV模型是否再现了HGPS小鼠模型中发现的血管的变化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
George A Truskey其他文献
George A Truskey的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('George A Truskey', 18)}}的其他基金
Vascular, Cardiac, and Lung Alveolar Human Microphysiological Systems for SARS-CoV-2 Drug Screening
用于 SARS-CoV-2 药物筛选的血管、心脏和肺泡人体微生理系统
- 批准号:
10166020 - 财政年份:2017
- 资助金额:
$ 46.21万 - 项目类别:
Developing An In Vitro Human Myobundle Model Of Rheumatoid Arthritis
开发类风湿关节炎的体外人体肌束模型
- 批准号:
9534005 - 财政年份:2017
- 资助金额:
$ 46.21万 - 项目类别:
Systemic Inflammation in Microphysiological Models of Muscle and Vascular Disease
肌肉和血管疾病微生理模型中的全身炎症
- 批准号:
9401783 - 财政年份:2017
- 资助金额:
$ 46.21万 - 项目类别:
Systemic Inflammation in Microphysiological Models of Muscle and Vascular Disease
肌肉和血管疾病微生理模型中的全身炎症
- 批准号:
10009489 - 财政年份:2017
- 资助金额:
$ 46.21万 - 项目类别:
In Vitro Human Tissue-Engineered Blood Vessel Disease Model of Progeria
早衰症体外人体组织工程血管疾病模型
- 批准号:
10445145 - 财政年份:2017
- 资助金额:
$ 46.21万 - 项目类别:
Systemic Inflammation in Microphysiological Models of Muscle and Vascular Disease
肌肉和血管疾病微生理模型中的全身炎症
- 批准号:
10013428 - 财政年份:2017
- 资助金额:
$ 46.21万 - 项目类别:
Systemic Inflammation in Microphysiological Models of Muscle and Vascular Disease
肌肉和血管疾病微生理模型中的全身炎症
- 批准号:
10471015 - 财政年份:2017
- 资助金额:
$ 46.21万 - 项目类别:
In Vitro Human Tissue-Engineered Blood Vessel Disease Model of Progeria
早衰症体外人体组织工程血管疾病模型
- 批准号:
9980460 - 财政年份:2017
- 资助金额:
$ 46.21万 - 项目类别:
In Vitro Human Tissue-Engineered Blood Vessel Disease Model of Progeria
早衰症体外人体组织工程血管疾病模型
- 批准号:
9929937 - 财政年份:2017
- 资助金额:
$ 46.21万 - 项目类别:
In Vitro Human Tissue-Engineered Blood Vessel Disease Model of Progeria
早衰症体外人体组织工程血管疾病模型
- 批准号:
10622613 - 财政年份:2017
- 资助金额:
$ 46.21万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 46.21万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 46.21万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 46.21万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 46.21万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 46.21万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 46.21万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 46.21万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 46.21万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 46.21万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 46.21万 - 项目类别:
Research Grant